Keymed Biosciences Inc.
2162.HK · HKSE
Market closed81.65-4.30 (-5.00%)
Key statistics
Previous close85.95
Open86.10
Day high88.20
Day low80.35
52-week high89.75
52-week low44.66
Market cap24.05B
Volume4.56M
Average volume2.91M
P/E ratio-38.65
Forward P/E—
EPS-2.11
Dividend yield0.00%
Market context
Why it moved
Shares of Keymed Biosciences (2162.HK) declined sharply today following news that its controlling shareholder has submitted a tender offer or sell-down request, raising concerns about potential significant share supply hitting the market and weighing heavily on investor sentiment.
What is happening
Recent company-specific developments and publisher coverage.
BioWorld News · July 17, 2026Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCsMoomoo · July 16, 2026Keymed Biosciences Expects Return to Profit in H1Latham & Watkins LLP · January 10, 2025Latham Advises Timberlyne Therapeutics on US$180 Million Series A Financing From KeyMed BiosciencesClifford Chance · August 13, 2024Clifford Chance advises Keymed Biosciences Inc. on out-licensing transaction with Belenos Biosciences Mt Newswire · July 16, 2026Keymed Biosciences Expects Return to Profit in H1 Mt Newswire · June 5, 2026Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close Mt Newswire · March 27, 2026Keymed Biosciences' Loss Deepens in 2025 Mt Newswire · March 24, 2026Keymed Biosciences Says Ouro Medicines to be Sold in $2.18 Billion Deal Mt Newswire · March 11, 2026Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%